{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:32:08Z","timestamp":1790674328304,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Russian Government to support the Program of Competitive Growth of Kazan Federal University"},{"name":"NIH R01","award":["DK108195"],"award-info":[{"award-number":["DK108195"]}]},{"DOI":"10.13039\/100013140","name":"Colorectal Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013140","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI Core Grant P30","award":["CA006927"],"award-info":[{"award-number":["CA006927"]}]},{"name":"DOD","award":["W81XWH-18-1-0148"],"award-info":[{"award-number":["W81XWH-18-1-0148"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pathogenic variants (PVs) in multiple genes are known to increase the risk of early-onset renal cancer (eoRC). However, many eoRC patients lack PVs in RC-specific genes; thus, their genetic risk remains undefined. Here, we determine if PVs in DNA damage response and repair (DDRR) genes are enriched in eoRC patients undergoing cancer risk assessment. Retrospective review of de-identified results from 844 eoRC patients, undergoing testing with a multi-gene panel, for a variety of indications, by Ambry Genetics. PVs in cancer-risk genes were identified in 12.8% of patients\u2014with 3.7% in RC-specific, and 8.55% in DDRR genes. DDRR gene PVs were most commonly identified in\n                    <jats:italic>CHEK2<\/jats:italic>\n                    ,\n                    <jats:italic>BRCA1, BRCA2,<\/jats:italic>\n                    and\n                    <jats:italic>ATM<\/jats:italic>\n                    . Among the 2.1% of patients with a\n                    <jats:italic>BRCA1<\/jats:italic>\n                    or\n                    <jats:italic>BRCA2<\/jats:italic>\n                    PV, &lt;\u200950% reported a personal history of hereditary breast or ovarian-associated cancer. No association between age of RC diagnosis and prevalence of PVs in RC-specific or DDRR genes was observed. Additionally, 57.9% patients reported at least one additional cancer; breast cancer being the most common (40.1% of females, 2.5% of males). Multi-gene testing including DDRR genes may provide a more comprehensive risk assessment in eoRC patients. Further validation is needed to characterize the association with eoRC.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-70449-5","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T06:10:29Z","timestamp":1597126229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Tiffiney R.","family":"Hartman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Demidova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy W.","family":"Lesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Speare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Golemis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeevani","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"70449_CR1","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1038\/537S98a","volume":"537","author":"G Shaw","year":"2016","unstructured":"Shaw, G. The silent disease. Nature537, S98\u2013S99. https:\/\/doi.org\/10.1038\/537S98a (2016).","journal-title":"Nature"},{"key":"70449_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin.70, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"70449_CR3","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136, E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210 (2015).","journal-title":"Int. J. Cancer"},{"key":"70449_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","volume":"67","author":"A Znaor","year":"2015","unstructured":"Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A. & Bray, F. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol.67, 519\u2013530. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.002 (2015).","journal-title":"Eur. Urol."},{"key":"70449_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/MOU.0b013e32832f0d40","volume":"19","author":"JA Coleman","year":"2009","unstructured":"Coleman, J. A. & Russo, P. Hereditary and familial kidney cancer. Curr. Opin. Urol.19, 478\u2013485. https:\/\/doi.org\/10.1097\/MOU.0b013e32832f0d40 (2009).","journal-title":"Curr. Opin. Urol."},{"key":"70449_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.urolonc.2008.11.001","volume":"27","author":"I Rosner","year":"2009","unstructured":"Rosner, I., Bratslavsky, G., Pinto, P. A. & Linehan, W. M. The clinical implications of the genetics of renal cell carcinoma. Urol. Oncol.27, 131\u2013136. https:\/\/doi.org\/10.1016\/j.urolonc.2008.11.001 (2009).","journal-title":"Urol. Oncol."},{"key":"70449_CR7","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1002\/cncr.30893","volume":"123","author":"KA Nguyen","year":"2017","unstructured":"Nguyen, K. A. et al. Advances in the diagnosis of hereditary kidney cancer: initial results of a multigene panel test. Cancer123, 4363\u20134371. https:\/\/doi.org\/10.1002\/cncr.30893 (2017).","journal-title":"Cancer"},{"key":"70449_CR8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.6004\/jnccn.2019.0054","volume":"17","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J. Natl. Compr. Cancer Netw.17, 1278\u20131285. https:\/\/doi.org\/10.6004\/jnccn.2019.0054 (2019).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"70449_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown, J. S., O\u2019Carrigan, B., Jackson, S. P. & Yap, T. A. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov.7, 20\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0860 (2017).","journal-title":"Cancer Discov."},{"key":"70449_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1590\/S1677-5538.IBJU.2016.0125","volume":"43","author":"WH Costa","year":"2017","unstructured":"Costa, W. H., Jabboure, G. N. & Cunha, I. W. Urological cancer related to familial syndromes. Int. Braz. J. Urol.43, 192\u2013201. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2016.0125 (2017).","journal-title":"Int. Braz. J. Urol."},{"key":"70449_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10689-012-9526-6","volume":"11","author":"M Aarnio","year":"2012","unstructured":"Aarnio, M. et al. Uroepithelial and kidney carcinoma in Lynch syndrome. Fam. Cancer11, 395\u2013401. https:\/\/doi.org\/10.1007\/s10689-012-9526-6 (2012).","journal-title":"Fam. Cancer"},{"key":"70449_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1200\/JCO.2011.39.5590","volume":"30","author":"AK Win","year":"2012","unstructured":"Win, A. K. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol.30, 958\u2013964. https:\/\/doi.org\/10.1200\/JCO.2011.39.5590 (2012).","journal-title":"J. Clin. Oncol."},{"key":"70449_CR13","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1001\/jama.2011.743","volume":"305","author":"V Bonadona","year":"2011","unstructured":"Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA305, 2304\u20132310. https:\/\/doi.org\/10.1001\/jama.2011.743 (2011).","journal-title":"JAMA"},{"issue":"238","key":"70449_CR14","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/j.urolonc.2015.11.021","volume":"34","author":"KL Stratton","year":"2016","unstructured":"Stratton, K. L. et al. Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes. Urol. Oncol.34(238), e231\u2013e237. https:\/\/doi.org\/10.1016\/j.urolonc.2015.11.021 (2016).","journal-title":"Urol. Oncol."},{"key":"70449_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15586\/jkcvhl.2018.101","volume":"5","author":"J Huszno","year":"2018","unstructured":"Huszno, J. & Kolosza, Z. Checkpoint kinase 2 (CHEK2) mutation in renal cell carcinoma: a single-center experience. J. Kidney Cancer VHL5, 19\u201323. https:\/\/doi.org\/10.15586\/jkcvhl.2018.101 (2018).","journal-title":"J. Kidney Cancer VHL"},{"key":"70449_CR16","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","volume":"4","author":"MI Carlo","year":"2018","unstructured":"Carlo, M. I. et al. Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma. JAMA Oncol.4, 1228\u20131235. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1986 (2018).","journal-title":"JAMA Oncol."},{"key":"70449_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jnci\/djp473","volume":"102","author":"L Baglietto","year":"2010","unstructured":"Baglietto, L. et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J. Natl. Cancer Inst.102, 193\u2013201. https:\/\/doi.org\/10.1093\/jnci\/djp473 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"70449_CR18","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","volume":"36","author":"SW Ten Broeke","year":"2018","unstructured":"Ten Broeke, S. W. et al. Cancer risks for PMS2-associated Lynch syndrome. J. Clin. Oncol.36, 2961\u20132968. https:\/\/doi.org\/10.1200\/JCO.2018.78.4777 (2018).","journal-title":"J. Clin. Oncol."},{"key":"70449_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4267\/2042\/37718","volume":"5","author":"J Varley","year":"2001","unstructured":"Varley, J. Li\u2013Fraumeni syndrome. Atlas Genet. Cytogenet. Oncol. Haematol.5, 76\u201377. https:\/\/doi.org\/10.4267\/2042\/37718 (2001).","journal-title":"Atlas Genet. Cytogenet. Oncol. Haematol."},{"key":"70449_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.juro.2015.02.081","volume":"194","author":"M Mork","year":"2015","unstructured":"Mork, M. et al. Lynch syndrome: a primer for urologists and panel recommendations. J. Urol.194, 21\u201329. https:\/\/doi.org\/10.1016\/j.juro.2015.02.081 (2015).","journal-title":"J. Urol."},{"key":"70449_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10689-012-9573-z","volume":"12","author":"PJ Barrow","year":"2013","unstructured":"Barrow, P. J. et al. The spectrum of urological malignancy in Lynch syndrome. Fam. Cancer12, 57\u201363. https:\/\/doi.org\/10.1007\/s10689-012-9573-z (2013).","journal-title":"Fam. Cancer"},{"key":"70449_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","volume":"32","author":"B Shuch","year":"2014","unstructured":"Shuch, B. et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J. Clin. Oncol.32, 431\u2013437. https:\/\/doi.org\/10.1200\/JCO.2013.50.8192 (2014).","journal-title":"J. Clin. Oncol."},{"key":"70449_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.humpath.2017.11.005","volume":"74","author":"T Clemmensen","year":"2018","unstructured":"Clemmensen, T. et al. Pathologic and clinical characteristics of early onset renal cell carcinoma. Hum. Pathol.74, 25\u201331. https:\/\/doi.org\/10.1016\/j.humpath.2017.11.005 (2018).","journal-title":"Hum. Pathol."},{"key":"70449_CR24","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1053\/j.gastro.2015.08.052","volume":"149","author":"S Arora","year":"2015","unstructured":"Arora, S. et al. Genetic variants that predispose to DNA double-strand breaks in lymphocytes from a subset of patients with familial colorectal carcinomas. Gastroenterology149, 1872-1883 e1879. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.052 (2015).","journal-title":"Gastroenterology"},{"key":"70449_CR25","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1053\/j.gastro.2010.01.054","volume":"138","author":"KW Jasperson","year":"2010","unstructured":"Jasperson, K. W., Tuohy, T. M., Neklason, D. W. & Burt, R. W. Hereditary and familial colon cancer. Gastroenterology138, 2044\u20132058. https:\/\/doi.org\/10.1053\/j.gastro.2010.01.054 (2010).","journal-title":"Gastroenterology"},{"key":"70449_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg, T. A. et al. Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas. Cell Rep.23, 239-254 e236. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.076 (2018).","journal-title":"Cell Rep."},{"key":"70449_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature536, 285\u2013291. https:\/\/doi.org\/10.1038\/nature19057 (2016).","journal-title":"Nature"},{"key":"70449_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/531210","author":"K Karczewski","year":"2019","unstructured":"Karczewski, K. et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv\nhttps:\/\/doi.org\/10.1101\/531210 (2019).","journal-title":"bioRxiv"},{"key":"70449_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/jso.24879","volume":"117","author":"NJ Kocher","year":"2018","unstructured":"Kocher, N. J., Rjepaj, C., Lehman, E. & Raman, J. D. Incidence and histologic features of mixed renal tumors. J. Surg. Oncol.117, 430\u2013433. https:\/\/doi.org\/10.1002\/jso.24879 (2018).","journal-title":"J. Surg. Oncol."},{"key":"70449_CR30","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1097\/PAS.0b013e3181831e68","volume":"32","author":"MB Amin","year":"2008","unstructured":"Amin, M. B. et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am. J. Surg. Pathol.32, 1822\u20131834. https:\/\/doi.org\/10.1097\/PAS.0b013e3181831e68 (2008).","journal-title":"Am. J. Surg. Pathol."},{"key":"70449_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2017.96","volume":"4","author":"SE Wobker","year":"2017","unstructured":"Wobker, S. E. & Williamson, S. R. Modern pathologic diagnosis of renal oncocytoma. J. Kidney Cancer VHL4, 1\u201312. https:\/\/doi.org\/10.15586\/jkcvhl.2017.96 (2017).","journal-title":"J. Kidney Cancer VHL"},{"key":"70449_CR32","unstructured":"Williams, G. M. & Lynch, D. T. in StatPearls (2020)."},{"key":"70449_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.pathol.2019.04.006","volume":"51","author":"SR Williamson","year":"2019","unstructured":"Williamson, S. R. Renal cell carcinomas with a mesenchymal stromal component: what do we know so far?. Pathology51, 453\u2013462. https:\/\/doi.org\/10.1016\/j.pathol.2019.04.006 (2019).","journal-title":"Pathology"},{"key":"70449_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00580-017-2455-x","volume":"26","author":"M Jalilvand","year":"2017","unstructured":"Jalilvand, M. et al. An association study between CHEK2 gene mutations and susceptibility to breast cancer. Comp. Clin. Pathol.26, 837\u2013845. https:\/\/doi.org\/10.1007\/s00580-017-2455-x (2017).","journal-title":"Comp. Clin. Pathol."},{"key":"70449_CR35","doi-asserted-by":"publisher","first-page":"294575","DOI":"10.1155\/2014\/294575","volume":"2014","author":"V Hale","year":"2014","unstructured":"Hale, V., Weischer, M. & Park, J. Y. CHEK2 (*) 1100delC mutation and risk of prostate cancer. Prostate Cancer2014, 294575. https:\/\/doi.org\/10.1155\/2014\/294575 (2014).","journal-title":"Prostate Cancer"},{"key":"70449_CR36","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1086\/375121","volume":"72","author":"H Meijers-Heijboer","year":"2003","unstructured":"Meijers-Heijboer, H. et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am. J. Hum. Genet.72, 1308\u20131314. https:\/\/doi.org\/10.1086\/375121 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"70449_CR37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/gcc.22162","volume":"53","author":"A Wojcicka","year":"2014","unstructured":"Wojcicka, A. et al. Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma. Genes Chromosomes Cancer53, 516\u2013523. https:\/\/doi.org\/10.1002\/gcc.22162 (2014).","journal-title":"Genes Chromosomes Cancer"},{"key":"70449_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10689-018-0070-x","volume":"17","author":"AH West","year":"2018","unstructured":"West, A. H. et al. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam. Cancer17, 495\u2013505. https:\/\/doi.org\/10.1007\/s10689-018-0070-x (2018).","journal-title":"Fam. Cancer"},{"key":"70449_CR39","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/ijc.30197","volume":"139","author":"AK Win","year":"2016","unstructured":"Win, A. K. et al. Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int. J. Cancer139, 1557\u20131563. https:\/\/doi.org\/10.1002\/ijc.30197 (2016).","journal-title":"Int. J. Cancer"},{"key":"70449_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.gene.2013.03.026","volume":"524","author":"F Ezgu","year":"2013","unstructured":"Ezgu, F., Krejci, P. & Wilcox, W. R. Mild clinical presentation and prolonged survival of a patient with fumarase deficiency due to the combination of a known and a novel mutation in FH gene. Gene524, 403\u2013406. https:\/\/doi.org\/10.1016\/j.gene.2013.03.026 (2013).","journal-title":"Gene"},{"key":"70449_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday, T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol.5, 387\u2013393. https:\/\/doi.org\/10.1016\/j.molonc.2011.07.001 (2011).","journal-title":"Mol. Oncol."},{"key":"70449_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00316","author":"RT Shroff","year":"2018","unstructured":"Shroff, R. T. et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis. Oncol.\nhttps:\/\/doi.org\/10.1200\/PO.17.00316 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"70449_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12894-019-0484-2","volume":"19","author":"I Park","year":"2019","unstructured":"Park, I., Shim, Y. S., Go, H., Hong, B. S. & Lee, J. L. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. BMC Urol.19, 51. https:\/\/doi.org\/10.1186\/s12894-019-0484-2 (2019).","journal-title":"BMC Urol."},{"key":"70449_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01051-z","author":"S Arora","year":"2019","unstructured":"Arora, S. et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv. Ther.\nhttps:\/\/doi.org\/10.1007\/s12325-019-01051-z (2019).","journal-title":"Adv. Ther."},{"key":"70449_CR45","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.18632\/oncotarget.23470","volume":"9","author":"SE Scanlon","year":"2018","unstructured":"Scanlon, S. E., Hegan, D. C., Sulkowski, P. L. & Glazer, P. M. Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma. Oncotarget9, 4647\u20134660. https:\/\/doi.org\/10.18632\/oncotarget.23470 (2018).","journal-title":"Oncotarget"},{"key":"70449_CR46","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.juro.2008.01.024","volume":"179","author":"JM Woldrich","year":"2008","unstructured":"Woldrich, J. M., Mallin, K., Ritchey, J., Carroll, P. R. & Kane, C. J. Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993\u20132004. J Urol179, 1709\u20131713. https:\/\/doi.org\/10.1016\/j.juro.2008.01.024 (2008) (discussion 1713).","journal-title":"J Urol"},{"key":"70449_CR47","doi-asserted-by":"publisher","first-page":"D840","DOI":"10.1093\/nar\/gkw971","volume":"45","author":"KJ Karczewski","year":"2017","unstructured":"Karczewski, K. J. et al. The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res.45, D840\u2013D845. https:\/\/doi.org\/10.1093\/nar\/gkw971 (2017).","journal-title":"Nucleic Acids Res."},{"key":"70449_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13073-017-0403-7","volume":"9","author":"Y Kobayashi","year":"2017","unstructured":"Kobayashi, Y. et al. Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation. Genome Med.9, 13. https:\/\/doi.org\/10.1186\/s13073-017-0403-7 (2017).","journal-title":"Genome Med."},{"key":"70449_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/gim.2016.90","volume":"19","author":"R Walsh","year":"2017","unstructured":"Walsh, R. et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet. Med.19, 192\u2013203. https:\/\/doi.org\/10.1038\/gim.2016.90 (2017).","journal-title":"Genet. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70449-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:32:14Z","timestamp":1670329934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70449-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70449"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70449-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.02.21.958256","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.F. has consulted for Invitae Corporation, and received speaker fees from AstraZeneca, M.J.H. performs collaborative research (with no funding) with the following: Myriad Genetics, Invitae Corporation, Ambry Genetics, Foundation Medicine, Inc. He also performs collaborative research (with no funding) and is part of a Precision Oncology Alliance funded by Caris Life Sciences (cover travel and meals at meetings), L.H., M.R. and V.S. are full-time salaried employees of Ambry Genetics. All other authors report no conflicts or disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13518"}}